The Lipid-Lowering Agents market in France has seen steady growth in recent years, driven by various factors including changing customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: French customers have shown a growing interest in preventive healthcare measures, including the use of lipid-lowering agents to reduce the risk of heart disease and stroke. This trend is supported by the high prevalence of cardiovascular disease in France, which has led to increased awareness and demand for effective treatments.
Trends in the market: The Lipid-Lowering Agents market in France is dominated by statins, which account for a significant portion of total sales. However, there has been a growing interest in newer, more expensive therapies such as PCSK9 inhibitors, which are seen as more effective in certain patient populations. This trend is expected to continue in the coming years, as more clinical data becomes available and physicians become more familiar with these newer treatments.
Local special circumstances: France has a strong tradition of socialized medicine, which has led to a highly regulated pharmaceutical market. This has created challenges for pharmaceutical companies looking to introduce new products, as the approval process can be lengthy and expensive. In addition, the French government has implemented cost-containment measures in recent years, which have put pressure on drug prices and profitability.
Underlying macroeconomic factors: The French economy has been relatively stable in recent years, with moderate growth and low unemployment. However, the country faces significant challenges in the form of an aging population and rising healthcare costs. This has led to increased pressure on healthcare providers to find cost-effective solutions, including the use of generic drugs and other lower-cost alternatives. As a result, pharmaceutical companies operating in France are likely to face increasing price pressure in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
